Navigation Links
MiMedx Group Announces Record Second Quarter Results

KENNESAW, Ga., July 26, 2012 /PRNewswire/ -- MiMedx Group, Inc.  (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the quarter ended June 30, 2012.

Highlights of Second Quarter 2012 Results include:

  • Revenue Increased 2.5 times over Second Quarter 2011
  • Adjusted EBITDA* Almost Tripled Over First Quarter 2012
  • Gross Margins Hit Record Level of 77%
  • The Company recorded record revenue of $4.9 million for the second quarter of 2012, a 153% or $3.0 million increase over second quarter of 2011 revenue of $1.9 million, and a 32% increase over first quarter of 2012 revenue of $3.7 million.  The Company's earnings before interest, taxes, depreciation, amortization and share-based compensation (Adjusted EBITDA*) for the quarter ended June 30, 2012, were a record high of $923,000, a $2.3 million improvement as compared to the Adjusted EBITDA loss of $1.4 million for the second quarter of 2011, and a 194% increase over the first quarter of 2012 Adjusted EBITDA of $314,000.

    For the 6th consecutive quarter, the Company reported improved gross margins. The Company's second quarter 2012 gross margins of 77% is a 21% improvement over second quarter 2011 gross margins of 56%, and this milestone is a 3% improvement over the Company's first quarter of 2012 gross margins of 74%. 

    Management Commentary on Second Quarter Results
    Parker H. "Pete" Petit, Chairman and CEO stated, "Following our first quarter milestone of achieving positive adjusted EBITDA for the first time, we are very pleased that we almost tripled that metric for the second quarter as a result of continued strong revenue growth and improving gross margins.  Our gross profit margins increased another 3% to 77%, which is approaching our goal of achieving 80% gross profit margins.  We increased spending on clinical trials during the quarter, and we will continue to focus heavily on gathering significant amounts of clinical data on our AmnioFix® and EpiFix® allografts.  This is the third consecutive quarter in which we have achieved our revenue goals, and we expect to continue that performance through the end of the year."

    "I extend my congratulations to our management team on what I consider to be an excellent quarter.  Managing this level of revenue growth is always a challenge; however, we have made a few very timely additions to our management team with some key executives that came from our former organizations.  We feel strongly that these new executives will complement the talents of our existing management team and enable us to smoothly sustain these levels of growth."

    "We had a solid quarter of orders for both of our amniotic tissue allografts, AmnioFix® and EpiFix®," commented Bill Taylor, President and COO. "We have focused on our placenta recovery network and Purion® Processing operations to ensure that the increasing number of orders for AmnioFix® and EpiFix® can consistently be filled to serve the growing demand.  We began the year with just under 50 employees, and as of today, we have expanded our work force to over 100 employees. This growth has been primarily in our tissue processing operations, tissue donation operations and additional sales and marketing associates to serve the expanding demand from physicians for our AmnioFix® and EpiFix® offerings."

    Balance Sheet and Cash Flow
    Cash and cash equivalents as of June 30, 2012, were $2.7 million, as compared to $3.0 million as of March 31, 2012, and $4.1 million, as of December 31, 2011.
    Cash flow from operating activities for the second quarter 2012 of a negative $311,000 represents the lowest quarterly operational cash burn in the Company's history.  During the quarter the Company invested $191,000 in capital equipment in support of the ramp up of tissue processing activities. Subsequent to the end of the quarter, the Company exercised its right to call 3.1 million warrants at an exercise price of $1.50 per share, which should result in a substantial increase in the Company's cash position. Warrant holders have until August 2, 2012, to decide to exercise their warrants.  The proceeds will be used to fund general corporate growth.

    Total Current Liabilities of $8.2 million were reduced after the end of the quarter by the payoff of a convertible note of $1.1 million related to the acquisition of Surgical Biologics, issuing 893,000 shares of MiMedx Common Stock and cash payments totaling $177,000. Also included in Current Liabilities is the estimated 2012 earnout of $4.2 million related to the Surgical Biologics acquisition to be paid in MiMedx Common Stock in April 2013.

    Also, on July 3, 2012, a total of 3.3 million Contingent Warrants at an exercise price of $.01 were voided per the terms of the 2012 Contingent Warrant agreement related to the trading price of the Company's Common Stock.

    "The voiding of the remaining contingent warrants, the calling of the $1.50 warrants and paying off the Surgical Biologics Note primarily through the issuance of MiMedx Common Stock serves to further strengthen the balance sheet and simplify our capital structure going forward," stated Mike Senken, Chief Financial Officer.

    GAAP Earnings
    For the quarter ended June 30, 2012, the Company recorded a Net Loss from Operations of $118,000 and a $749,000 loss for the six months ended June 30, 2012. This represents a $2.3 million improvement over the second quarter of 2011 and a $4.9 million improvement over the six months ended June 30, 2011. The Net Loss for the quarter was $744,000 or $0.01 per diluted common share, a $1.8 million improvement as compared to the Net Loss of $2.5 million, or $0.03 per diluted common share, recorded for the quarter ended June 30, 2011. The Net Loss for the six months ended June 30, 2012 of $1.8 million represents a $4 million improvement as compared to the Net Loss of $5.8 million, or $0.08 per diluted common share, recorded for the six months ended June 30, 2011. Included in reported Net Loss is non-cash related financing expense associated with the debt discount of $473,000 for the quarter and $783,000 for the six months ended June 30, 2012. This expense will continue to be amortized over the life of the convertible notes.

    Use of Non-GAAP Financial Measures
    Management has disclosed adjusted financial measurements in this press announcement that present financial information that is not in accordance with generally accepted accounting principles (GAAP). These measurements are not a substitute for GAAP measurements, although Company management uses these measurements as aids in monitoring the Company's on-going financial performance from quarter-to-quarter and year-to-year on a regular basis, and for benchmarking against other medical technology companies. Adjusted EBITDA*is earnings before interest, taxes, depreciation, amortization and share-based compensation. For a reconciliation of this non-GAAP financial measure to the most directly comparable financial measure, see accompanying table to this release. Adjusted financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.

    Earnings Call
    MiMedx management will host a live broadcast of its second quarter of 2012 results conference call on Thursday, July 26, 2012, beginning at 10:30 a.m. eastern time.  A listen-only simulcast of the MiMedx Group conference call will be available online at the Company's website at or at  A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast.  The replay can also be found on the Company's website at or at

    About the Company
    MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion® Process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant for homologous use. Surgical Biologics is the leading supplier of amniotic tissue, having supplied over 90,000 implants to date to distributors and OEMs for application in the Ophthalmic, Orthopedics, Spine, Wound Care and Dental sectors of healthcare.

    Safe Harbor Statement
    This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes.  Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements include, but are not limited to, the anticipated continued growth in demand for the Company's tissue offerings and the Company's ability to smoothly sustain such growth, the Company's ability to continue to improve its gross margins and achieve its revenue goals through the end of the year, and the ability to fill orders to meet anticipated demand. These statements are based on current information and belief, and are not guarantees of future performance.  Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the anticipated demand for the Company's tissue offerings does not materialize as expected, that, despite the hiring of new executives, the Company cannot smoothly sustain the anticipated growth, that the Company may not be able to improve upon or sustain its gross margins, that the Company many not be able to timely fill orders to meet anticipated demand, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2011. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.  MIMEDX GROUP, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)Three Months Ended June 30,Six Months Ended June 30,2012201120122011REVENUES:Net sales$ 4,884,256$ 1,929,399$ 8,590,064$ 2,972,886OPERATING COSTS AND EXPENSES:Cost of products sold1,114,926844,9412,073,7811,555,058Research and development expenses503,086791,952910,1581,754,176Selling, general and administrative expenses3,383,7602,708,9416,355,0065,336,435LOSS FROM OPERATIONS(117,516)(2,416,435)(748,881)(5,672,783)OTHER INCOME (EXPENSE), netFinancing expense associated with the debt discount recognizedin connection with the senior secured promissory notes(472,749)-(783,226)-Interest expense, net(153,804)(87,070)(305,614)(178,284)LOSS BEFORE INCOME TAXES(744,069)(2,503,505)(1,837,721)(5,851,067)Income taxes----NET LOSS$ (744,069)$(2,503,505)$(1,837,721)$(5,851,067)Net loss per common shareBasic and diluted$
    (0.08)Shares used in computing net loss per common shareBasic and diluted79,952,54271,819,01777,416,07371,098,976See notes to condensed consolidated financial statements  

    MIMEDX GROUP, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETSASSETSJune 30,2012December 31,(unaudited)2011Current assets:Cash and cash equivalents

    $   2,654,694$
    4,112,326Accounts receivable, net

    3,946,3331,891,919Inventory, net

    961,939712,602Prepaid expenses and other current assets

    292,223164,664Total current assets

    7,855,1896,881,511Property and equipment, net of accumulated depreciation of $2,045,964and $1,814,473, respectively


    4,040,4434,040,443Intangible assets, net of accumulated amortization of $4,136,469and $3,468,515, respectively

    14,422,53115,090,485Deposits and other long term assets

    204,803214,342Total assets

    $ 27,471,686$   27,096,192LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable and accrued expenses

    $   1,902,349$
    2,300,638Other current liabilities

    69,9816,620Convertible line of credit with related party, net of unamortized
    discount of $398,899 and $46,746, respectively, plus accrued interest
    of $75,137 and $42,726, respectively

    976,2381,295,980Convertible debt related to acquisition, net of unamortized discount of
    $3,821 and $170,509, respectively, plus accrued interest of $69,808
    and $49,315, respectively

    1,065,9871,128,806Current portion of earn-out liability payable In MiMedx common stock

    4,225,2803,185,223Total current liabilities

    8,239,8357,917,267Earn-out liability payable in MiMedx common stock, net of current portion

    -4,225,280Convertible Senior Secured Promissory Notes, net of unamortized
    discount of $1,818,446 and $2,263,145, respectively, plus accrued
    interest of$61,933 and $7,732, respectively

    3,243,4872,744,587Other liabilities

    320,055312,493Total liabilities

    11,803,37715,199,627Commitments and contingencies (Note 12)

    --Stockholders' equity:Preferred stock; $.001 par value; 5,000,000 shares authorized and 0
    shares issued and outstanding

    --Common stock; $.001  par value; 110,000,000 shares authorized;
    81,052,359 issued and 81,002,359 outstanding for 2012 and
    74,306,895 issued and 74,256,895 outstanding for 2011

    81,05274,307Additional paid-in capital

    79,471,32473,868,604Treasury stock (50,000 shares at cost)

    (25,000)(25,000)Accumulated deficit

    (63,859,067)(62,021,346)Total stockholders' equity

    15,668,30911,896,565Total liabilities and stockholders' equity

    $ 27,471,686$   27,096,192See notes to condensed consolidated financial statementsMiMedx Group, Inc. and SubsidiariesNon-GAAP Financial Measures and ReconciliationAs used herein, "GAAP", refers to generally accepted accounting principles in the United States.  We use various numerical measures in conference calls, investor meetings and other forums which are or may be considered "Non-GAAP financial measures" under Regulation G.  We have provided below for your reference, supplemental financial disclosure for these measures, including the most directly comparable GAAP measure and an associated reconciliation. 

    Reconciliation of Net Loss to "Adjusted EBITDA" defined as Earnings before Interest, Taxes, Depreciation, Amortization and Share Based Compensation:


     Three Months Ended June 30,Six Months Ended June 30,2012201120122011Net Loss (Per GAAP)

    (744,069)$(2,503,505)$(1,837,721)$(5,851,067)Add back:Income Taxes

    ----Financing expense associated with beneficial conversion of notepayable issued in conjunction with acquisition

    86,33560,599166,688133,517Financing expense associated with beneficial conversion of Lineof Credit with Related Party

    150,880-162,303-Financing expense associated with beneficial conversion ofSenior Secured Promissory Note

    230,744-444,698-Other interest expense, net

    158,59426,471315,15134,809Depreciation Expense

    121,103115,682231,491231,862Amortization Expense

    333,977333,977667,954667,954Employee Share Based Compensation

    478,442429,096878,491809,469Other Share Based Compensation

    106,773114,648207,709222,208Earnings/(Loss) Before Interest, Taxes, Depreciation, Amortizationand Share-Based Compensation

    922,779$(1,423,032)$  1,236,764$(3,751,248) 

    SOURCE MiMedx, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related biology technology :

    1. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
    2. MiMedx Group Completes $5,000,000 Private Placement
    3. MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
    4. MiMedx to Present at American Academy of Orthopaedic Surgeons Annual Meeting
    5. MiMedx Group Announces 2011 Results
    6. MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix®
    7. MiMedx Exceeds Revenue Goal for First Quarter of 2012
    8. MiMedx Group Announces Record First Quarter Results
    9. MiMedx Group, Inc. Announces Release Date for 2012 Second Quarter Results
    10. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
    11. BioNeutral Group Receives $400,000 in Equity Financing
    Post Your Comments:
    (Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
    (Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
    (Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... maintain healthy metabolism. But unless it is bound to proteins, copper is also ... Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study ...
    (Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software solutions leader SAP ... states to develop and pitch their BIG ideas to improve health and wellness in ... for votes to win the title of SAP's Teen Innovator, an all-expenses paid trip ...
    Breaking Biology Technology:
    (Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
    (Date:10/29/2015)... -- Connected health pioneer, Joseph C. Kvedar , MD, ... and wellness, and the business opportunities that arise from ... of Healthy Things . Long before health and ... Kvedar, vice president, Connected Health, Partners HealthCare, was creating ... from the hospital or doctor,s office into the day-to-day ...
    (Date:10/27/2015)... SAN JOSE, Calif. , Oct. 27, 2015 /PRNewswire/ ... human interface solutions, today announced that Google has adopted ... family of touch controller solutions to power its newest ... Nexus 6P by Huawei. --> ... ecosystem partners like Google to provide strategic collaboration in ...
    Breaking Biology News(10 mins):